HRP20231641T1 - Farmaceutski pripravak koji sadrži mitotan za oralnu primjenu za liječenje adrenokortikalnog karcinoma i cushingovog sindroma - Google Patents
Farmaceutski pripravak koji sadrži mitotan za oralnu primjenu za liječenje adrenokortikalnog karcinoma i cushingovog sindroma Download PDFInfo
- Publication number
- HRP20231641T1 HRP20231641T1 HRP20231641TT HRP20231641T HRP20231641T1 HR P20231641 T1 HRP20231641 T1 HR P20231641T1 HR P20231641T T HRP20231641T T HR P20231641TT HR P20231641 T HRP20231641 T HR P20231641T HR P20231641 T1 HRP20231641 T1 HR P20231641T1
- Authority
- HR
- Croatia
- Prior art keywords
- cyclodextrin
- mitotane
- oil phase
- formulation
- mixtures
- Prior art date
Links
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 title claims 9
- 229960000350 mitotane Drugs 0.000 title claims 9
- 208000014311 Cushing syndrome Diseases 0.000 title claims 2
- 208000020990 adrenal cortex carcinoma Diseases 0.000 title claims 2
- 208000007128 adrenocortical carcinoma Diseases 0.000 title claims 2
- 201000009395 primary hyperaldosteronism Diseases 0.000 title claims 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 229920000858 Cyclodextrin Polymers 0.000 claims 10
- 239000000203 mixture Substances 0.000 claims 10
- 239000003921 oil Substances 0.000 claims 7
- 235000019198 oils Nutrition 0.000 claims 7
- 238000009472 formulation Methods 0.000 claims 6
- 239000012071 phase Substances 0.000 claims 6
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims 6
- 239000000839 emulsion Substances 0.000 claims 5
- 238000002360 preparation method Methods 0.000 claims 4
- 229940124532 absorption promoter Drugs 0.000 claims 3
- 239000001116 FEMA 4028 Substances 0.000 claims 2
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims 2
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims 2
- 229960004853 betadex Drugs 0.000 claims 2
- 239000006184 cosolvent Substances 0.000 claims 2
- 229940097362 cyclodextrins Drugs 0.000 claims 2
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 claims 2
- 229940080345 gamma-cyclodextrin Drugs 0.000 claims 2
- 239000008187 granular material Substances 0.000 claims 2
- GHHURQMJLARIDK-UHFFFAOYSA-N 2-hydroxypropyl octanoate Chemical compound CCCCCCCC(=O)OCC(C)O GHHURQMJLARIDK-UHFFFAOYSA-N 0.000 claims 1
- 208000005676 Adrenogenital syndrome Diseases 0.000 claims 1
- 208000008448 Congenital adrenal hyperplasia Diseases 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 1
- SHBUUTHKGIVMJT-UHFFFAOYSA-N Hydroxystearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OO SHBUUTHKGIVMJT-UHFFFAOYSA-N 0.000 claims 1
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 claims 1
- 229920001214 Polysorbate 60 Polymers 0.000 claims 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 claims 1
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 claims 1
- 239000010775 animal oil Substances 0.000 claims 1
- 239000008346 aqueous phase Substances 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-M decanoate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 claims 1
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 claims 1
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- 150000002170 ethers Chemical class 0.000 claims 1
- 229940080812 glyceryl caprate Drugs 0.000 claims 1
- 229940087068 glyceryl caprylate Drugs 0.000 claims 1
- 239000007902 hard capsule Substances 0.000 claims 1
- -1 hydroxypropyl Chemical group 0.000 claims 1
- 229940072106 hydroxystearate Drugs 0.000 claims 1
- 229960003511 macrogol Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008185 minitablet Substances 0.000 claims 1
- QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 claims 1
- 239000008188 pellet Substances 0.000 claims 1
- 239000008389 polyethoxylated castor oil Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- GHBFNMLVSPCDGN-UHFFFAOYSA-N rac-1-monooctanoylglycerol Chemical compound CCCCCCCC(=O)OCC(O)CO GHBFNMLVSPCDGN-UHFFFAOYSA-N 0.000 claims 1
- WBHHMMIMDMUBKC-QJWNTBNXSA-M ricinoleate Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCCC([O-])=O WBHHMMIMDMUBKC-QJWNTBNXSA-M 0.000 claims 1
- 229940066675 ricinoleate Drugs 0.000 claims 1
- 239000007901 soft capsule Substances 0.000 claims 1
- 230000007928 solubilization Effects 0.000 claims 1
- 238000005063 solubilization Methods 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 229950004959 sorbitan oleate Drugs 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 235000015112 vegetable and seed oil Nutrition 0.000 claims 1
- 239000008158 vegetable oil Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/02—Halogenated hydrocarbons
- A61K31/025—Halogenated hydrocarbons carbocyclic
- A61K31/03—Halogenated hydrocarbons carbocyclic aromatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (10)
1. Formulacija suhe emulzije mitotana koja sadrži:
Uljnu fazu obogaćenu mitotanom i ciklodekstrinom koja sadrži ili ne sadrži suotapalo i/ili promotora apsorpcije.
2. Formulacija prema patentnom zahtjevu 1, naznačena time što je uljna faza biljno ulje ili njihove mješavine, životinjsko ulje ili njihove mješavine i/ili morsko ulje ili njihove mješavine prisutni su u nižem sadržaju od 50% težine.
3. Formulacija prema patentnom zahtjevu 1, naznačena time što uljna faza sadrži promotore apsorpcije i/ili suotapala koja su odabrana na primjer između sljedećih spojeva: gliceril kaprilat/kaprat, makro golglicerol hidroksistearat, makrogolglicerol ricinoleat (Cremophor EL®), polioksietilen sorbitan oleat, dietilen glikol monoetil eter, propilen glikol monokaprilat, apsolutni etanol i makrogol 800 do 300, a koji su prisutni u sadržaju od 10 do 20% težine.
4. Formulacija prema patentnom zahtjevu 1, naznačena time što je ciklodekstrin odabran između a-ciklodekstrina, β-ciklodekstrina i γ-ciklodekstrina i time što su derivati ciklodekstrina odabrani između hidroksipropilnih, metiliranih, etiliranih, sulfobutiliranih eter derivata ili acetiliranih a-ciklodekstrina, β-ciklodekstrina i γ-ciklodekstrina i binarne ili ternarne smjese navedenih ciklodekstrina i navedenih derivata ciklodekstrina, i prisutni su u sadržaju većem od 45% težine.
5. Farmaceutski i veterinarski pripravak koji sadrži formulaciju suhe emulzije mitotana kao što je definirana u jednom od patentnih zahtjeva 1 do 4.
6. Pripravak prema patentnom zahtjevu 5, naznačen time što je u obliku prikladnom za davanje oralnim putem.
7. Pripravak prema patentnom zahtjevu 6, naznačen time što je predstavljen u različitim oblicima, obloženim ili ne: prašak, granulat, mini-tablete, granule (peleti), tablete, kapsule.
8. Formulacija u obliku mekih kapsula ili tvrdih kapsula koja sadrži mitotan u uljnoj fazi i ciklodekstrin, kako je definirano u bilo kojem od patentnih zahtjeva 2 do 4.
9. Pripravak prema bilo kojem od patentnih zahtjeva 6 do 7, naznačen time što se koristi u liječenju karcinoma kore nadbubrežne žlijezde, kongenitalne adrenalne hiperplazije i Cushingovog sindroma.
10. Postupak za pripremu suhe emulzije mitotana prema patentnim zahtjevima 2 do 4 za formiranje sustava davanja mitotana, što uključuje solubilizaciju mitotana u uljnoj fazi s ili bez suotapala, dodavanje ciklodekstrina u uljnu fazu s ili bez promotora apsorpcije, dodavanje vodenaste faze za dobivanje primarne U/V emulzije zatim suhe emulzije na bazi mitotana, sušenje i kalibracija zrna.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1912084A FR3102356B1 (fr) | 2019-10-28 | 2019-10-28 | Composition pharmaceutique comprenant le mitotane pour une administration par voie orale pour le traitement du carcinome corticosurrenalien et du syndrome de cushing |
| PCT/IB2020/059218 WO2021084345A1 (fr) | 2019-10-28 | 2020-10-01 | Composition pharmaceutique comprenant le mitotane pour une administration par voie orale pour le traitement du carcinome corticosurrenalien et du syndrome de cushing |
| EP20786346.5A EP4051249B1 (fr) | 2019-10-28 | 2020-10-01 | Composition pharmaceutique comprenant le mitotane pour une administration par voie orale pour le traitement du carcinome corticosurrenalien et du syndrome de cushing |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20231641T1 true HRP20231641T1 (hr) | 2024-03-15 |
Family
ID=69810998
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20231641TT HRP20231641T1 (hr) | 2019-10-28 | 2020-10-01 | Farmaceutski pripravak koji sadrži mitotan za oralnu primjenu za liječenje adrenokortikalnog karcinoma i cushingovog sindroma |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20240058277A1 (hr) |
| EP (1) | EP4051249B1 (hr) |
| JP (1) | JP2023500494A (hr) |
| KR (1) | KR20220088904A (hr) |
| CN (1) | CN114599347B (hr) |
| AU (1) | AU2020377140A1 (hr) |
| CA (1) | CA3153794A1 (hr) |
| ES (1) | ES2966481T3 (hr) |
| FR (1) | FR3102356B1 (hr) |
| HR (1) | HRP20231641T1 (hr) |
| HU (1) | HUE064738T2 (hr) |
| MX (1) | MX2022004255A (hr) |
| PL (1) | PL4051249T4 (hr) |
| RS (1) | RS64962B1 (hr) |
| WO (1) | WO2021084345A1 (hr) |
| ZA (1) | ZA202205923B (hr) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4146648A (en) * | 1977-07-14 | 1979-03-27 | Bristol-Myers Company | Chemotherapeutic composition |
| IL101007A (en) * | 1992-02-18 | 1997-08-14 | Pharmos Ltd | Dry stable compositions prepared by lyophilization |
| ATE446087T1 (de) * | 2006-01-23 | 2009-11-15 | Yissum Res Dev Co | Mikrokügelchen mit nanokapseln, die ein lipophiles arzneimittel enthalten |
| EP2255786A1 (en) | 2009-05-25 | 2010-12-01 | HRA Pharma LLC | Self-microemulsifying mitotane composition |
| US20130317117A1 (en) | 2010-11-24 | 2013-11-28 | Pharmaceutics International, Inc. | Self micro-emulsifying drug delivery system with increased bioavailability |
| CN105250221B (zh) * | 2014-07-14 | 2018-06-19 | 天津药物研究院 | 一种利可瑞特干乳剂及其制备方法 |
-
2019
- 2019-10-28 FR FR1912084A patent/FR3102356B1/fr active Active
-
2020
- 2020-10-01 CN CN202080074567.7A patent/CN114599347B/zh active Active
- 2020-10-01 EP EP20786346.5A patent/EP4051249B1/fr active Active
- 2020-10-01 ES ES20786346T patent/ES2966481T3/es active Active
- 2020-10-01 AU AU2020377140A patent/AU2020377140A1/en active Pending
- 2020-10-01 RS RS20231201A patent/RS64962B1/sr unknown
- 2020-10-01 MX MX2022004255A patent/MX2022004255A/es unknown
- 2020-10-01 WO PCT/IB2020/059218 patent/WO2021084345A1/fr active Application Filing
- 2020-10-01 US US17/639,578 patent/US20240058277A1/en active Pending
- 2020-10-01 JP JP2022525536A patent/JP2023500494A/ja active Pending
- 2020-10-01 KR KR1020227017439A patent/KR20220088904A/ko unknown
- 2020-10-01 HR HRP20231641TT patent/HRP20231641T1/hr unknown
- 2020-10-01 HU HUE20786346A patent/HUE064738T2/hu unknown
- 2020-10-01 PL PL20786346.5T patent/PL4051249T4/pl unknown
- 2020-10-01 CA CA3153794A patent/CA3153794A1/en active Pending
-
2022
- 2022-05-27 ZA ZA2022/05923A patent/ZA202205923B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20240058277A1 (en) | 2024-02-22 |
| WO2021084345A1 (fr) | 2021-05-06 |
| JP2023500494A (ja) | 2023-01-06 |
| PL4051249T3 (pl) | 2024-04-08 |
| CN114599347A (zh) | 2022-06-07 |
| EP4051249C0 (fr) | 2023-09-13 |
| AU2020377140A1 (en) | 2022-06-09 |
| CN114599347B (zh) | 2024-07-12 |
| HUE064738T2 (hu) | 2024-04-28 |
| EP4051249A1 (fr) | 2022-09-07 |
| MX2022004255A (es) | 2022-05-06 |
| KR20220088904A (ko) | 2022-06-28 |
| EP4051249B1 (fr) | 2023-09-13 |
| FR3102356B1 (fr) | 2021-09-17 |
| RS64962B1 (sr) | 2024-01-31 |
| CA3153794A1 (en) | 2021-05-06 |
| FR3102356A1 (fr) | 2021-04-30 |
| ZA202205923B (en) | 2023-04-26 |
| PL4051249T4 (pl) | 2024-04-08 |
| ES2966481T3 (es) | 2024-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kayaci et al. | Enhanced thermal stability of eugenol by cyclodextrin inclusion complex encapsulated in electrospun polymeric nanofibers | |
| Gao et al. | Preparation, characterization, pharmacokinetics, and tissue distribution of curcumin nanosuspension with TPGS as stabilizer | |
| JP2010525059A5 (hr) | ||
| HRP20210034T1 (hr) | Farmaceutski pripravci koji sadrže meloksikam i rizatriptan | |
| Santos et al. | Methyl-β-cyclodextrin inclusion complex with β-caryophyllene: preparation, characterization, and improvement of pharmacological activities | |
| Mallick et al. | Current perspectives of solubilization: potential for improved bioavailability | |
| US20160151243A1 (en) | Soft shell capsule and process for its manufacture | |
| JP2016510019A5 (hr) | ||
| Arora et al. | Cyclodextrin-based delivery systems for dietary pharmaceuticals | |
| WO2015198257A1 (en) | Stable carfilzomib injection | |
| CN104306329A (zh) | 一种盐酸溴己新注射液及其制备方法和用途 | |
| JP2019504056A5 (hr) | ||
| KR101342486B1 (ko) | 신규한 연질 젤라틴 캡슐 | |
| Kriplani et al. | Formulation optimization and characterization of transdermal film of curcumin by response surface methodology | |
| JP6235603B2 (ja) | 消炎性および／または免疫抑制性活性成分としてのデルフィニジン複合体 | |
| Arruda et al. | Native cyclodextrins and their derivatives as potential additives for food packaging: A review | |
| HRP20231641T1 (hr) | Farmaceutski pripravak koji sadrži mitotan za oralnu primjenu za liječenje adrenokortikalnog karcinoma i cushingovog sindroma | |
| JP2014501576A5 (hr) | ||
| CN109922807A (zh) | 维拉佐酮包合物及其组合物和制备方法 | |
| JP2016088912A (ja) | Ｗ／ｏ／ｗ型エマルション | |
| EP2815744A1 (en) | Gastro-resistant soft shell capsule and process for its manufacture | |
| JP2016507535A5 (hr) | ||
| WO2019097413A1 (en) | Stable non-aqueous pharmaceutical compositions | |
| Arora et al. | Cyclodextrin-based carriers for delivery of dietary phytochemicals | |
| AU2014204878B2 (en) | Voriconazole inclusion complexes |